Merck Enters Two Strategic Collaborations to Strengthen AI-driven Drug Discovery

2023年09月20日 22:24:33 来自: (0)参与

Not intended for US-, Canada- or UK-based media

Partnerships with BenevolentAI and Exscientia to drive accelerated drug discovery with higher probability of success
Access to end-to-end AI platform capabilities to generate novel development candidates in oncology, neurology and immunology
AI-powered R&D integral part of delivering on ambition of bringing more medicines to more patients, faster

DARMSTADT, Germany--(BUSINESS WIRE)--Merck, a leading science and technology company, today announced two new strategic drug discovery collaborations aimed at harnessing powerful artificial intelligence (AI)-driven design and discovery capabilities, further advancing the company’s research efforts. The partnerships, with BenevolentAI, London, U.K., and Exscientia, Oxford, U.K., are expected to generate several novel clinical development drug candidates with first-in-class and best-in-class potential in key therapeutic areas of oncology, neurology and immunology.

“With the convergence of science, data, and AI, we're determined to fast-track the development of new and truly innovative candidates, forging a path to previously unimaginable medical breakthroughs,” said Danny Bar-Zohar, Global Head of Research & Development and Chief Medical Officer for the Healthcare business sector of Merck. “The partnerships with industry-leading AI technology firms BenevolentAI and Exscientia will complement our internal research capabilities and expertise, aligning with our broader strategy to enhance R&D productivity and the output of our pipeline in a sustainable manner.”

Under the terms of the agreements, three potential first-in-class and best-in-class targets have been selected to initiate each partnership with the possibility of identifying and nominating additional targets in the future. The collaborative efforts are focused on advancing small molecule development candidates which Merck will select for further pre-clinical and clinical development. Both partners will each receive low double digit million US dollar upfront payments and will be eligible for discovery, development, regulatory and commercial milestone payments and tiered royalties based on net sales.

Merck systematically explores data science and AI approaches to accelerate the discovery and delivery of breakthrough medicines. Integrating AI across R&D processes from identifying targets to clinical trials and product lifecycle management, is aimed at transforming drug discovery and development, bringing new medicines to patients faster and with higher probability of success. As the field evolves Merck will continue to deepen its existing AI and advanced analytics expertise while expanding partnerships and collaborations, ensuring the company remains at the forefront of innovation.

All Merck press releases are distributed by e-mail at the same time they become available on the Merck website. Please go to www.merckgroup.com/subscribe to register online, change your selection or discontinue this service.

About Merck

Merck, a leading science and technology company, operates across life science, healthcare and electronics. More than 64,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From providing products and services that accelerate drug development and manufacturing as well as discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2022, Merck generated sales of € 22.2 billion in 66 countries.

Scientific exploration and responsible entrepreneurship have been key to Merck’s technological and scientific advances. This is how Merck has thrived since its founding in 1668. The founding family remains the majority owner of the publicly listed company. Merck holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the business sectors of Merck operate as MilliporeSigma in life science, EMD Serono in healthcare, and EMD Electronics in electronics.

相关新闻
天涯网友:㎜  旧梦失词
评论:生活就像新闻联播,不是换台就能逃避的了。

淘宝网友:身軆被我所用
评论:> 有人争取,就会有人失去

网易网友:冷笑你的无知
评论:长大成人这件事最恐怖的地方之一,在于,你或许会变成自己曾经最看不起的那种人。

其它网友:猥琐 先森 Lasa°
评论:所谓长大、就是把原本看重的东西看轻一点、原本看轻的东西看重点...

天猫网友:半日情obsessIOn
评论:恋爱需要实习,而两个人分手则需要练习!

凤凰网友:Corner. [小角落]
评论:> 我说:要有上班以外的生活!于是,老婆告诉我这个可以有、于是:我有了加班!

搜狐网友:heart┃ 锁心
评论:我说过我爱你。没说我只爱你。

腾讯网友:谢谢你给的痛
评论:昔日迎风尿三丈、如今顺风尽湿鞋。

猫扑网友:﹌假装俄狠好
评论:破锅自有破锅盖,尼姑自有和尚爱

本网网友:心悲 2/2star°
评论:别以为遇见我就是你旳缘,也可能是你旳坎。

新闻转自网络媒体,如有侵权,请与我们联系:1160322105@qq.com责编:admin